AstraZeneca expects to have more than 100 million doses of its COVID-19 vaccine ready this month, which it has developed in collaboration with the University of Oxford, with production increasing to over 200 million a month from April, said today the CEO of Pascal Soriot.
Mene Pangalos, head of biopharmaceutical research and development for the UK pharmaceutical industry, said the company was awaiting information on the final stage of testing its vaccine in the US before the end of March.
AstraZeneca predicts faster profit growth this year as strong demand for its cancer treatment and other new treatments boosts the pharmaceutical industry, which has pledged not to make a profit from its coronavirus vaccine during the pandemic.
According to the company, it expects its revenue for 2021 to increase at a low double-digit rate and its core earnings to $ 5 per share from $ 4.75.
